Apexigen To Present At Piper Jaffray’s 30th Annual Healthcare Conference
San Carlos, CA – November 26, 2018 – Apexigen, Inc., a clinical-stage biopharmaceutical company, today announced that Xiaodong Yang, M.D., Ph.D., President and Chief Executive Officer, will present at Piper Jaffray’s 30th Annual Healthcare Conference on Tuesday, November 27, 2018 at 3:30 PM ET in New York, NY.
Apexigen is a clinical-stage biopharmaceutical company discovering and developing a new generation of antibody therapeutics for oncology, with an emphasis on new immuno-oncology agents that could harness the patient’s immune system to combat and eradicate cancer. The Company’s lead immuno-oncology therapeutic APX005M and the additional preclinical programs were discovered using APXiMAB™, Apexigen’s proprietary product discovery platform. This platform has enabled the Company and its collaboration partners to discover and develop high-quality therapeutic antibodies against a variety of molecular targets, including targets that are difficult to drug with conventional antibody technologies. Seven product candidates discovered using APXiMAB™ are currently in clinical development, either internally by Apexigen or by its partners. For more information, please visit www.apexigen.com.
Vice President, Business Development